Evidence map›Paper›PMID 38010476›Full record

ArticleJournal of natural medicines2024

Kamikihito reduces β-amyloid

Takumi Nagamatsu, Kaori Kubota, Takuya Watanabe, Shutaro Katsurabayashi, Katsunori Iwasaki

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Takumi Nagamatsu *Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Kaori Kubota *Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. kkubota@fukuoka-u.ac.jp.ORCID http://orcid.org/0000-0003-2049-600X
Takuya WatanabeDepartment of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.ORCID http://orcid.org/0000-0003-0131-8646
Shutaro KatsurabayashiDepartment of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.ORCID http://orcid.org/0000-0002-8595-5820
Katsunori IwasakiDepartment of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Fukuoka University · JP

Funding

Japan Society for the Promotion of Science 16K08315Japan Society for the Promotion of Science 23K06203Japan Society for the Promotion of Science 23K06204Japan Society for the Promotion of Science 23K06249Tsumura and Company 20071Tsumura and Company 20091
6 · The paper itself

Abstract

The Japanese herbal medicine kamikihito (KKT) is widely used for insomnia, anorexia, anemia, and depression. Recently, the efficacy of KKT against Alzheimer's disease (AD) has been demonstrated in clinical and non-clinical studies. To address the mechanism underlying the effect of KKT on AD, we examined the effects of KKT in β-amyloid (Aβ)

Indexed as

Alzheimer DiseaseDrugs, Chinese HerbalAmyloid beta-PeptidesAxonsBrain-Derived Neurotrophic FactorHumansNeuronsAmyloid beta-PeptidesBrain-Derived Neurotrophic FactorDrugs, Chinese Herbalkamikihi-toAxonal atrophyBeta amyloidBrain-derived neurotrophic factor (Bdnf)Kamikihito (KKT)Nerve growth factor (Ngf)

Identifiers

PMID38010476
OpenAlexW4389043088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.